Edge Therapeutics Inc Share Price Nasdaq
Equities
US2798701098
Biotechnology & Medical Research
Sales 2024 * | - | Sales 2025 * | 275K 21.92M | Capitalization | 140M 11.17B |
---|---|---|---|---|---|
Net income 2024 * | -51M -4.07B | Net income 2025 * | -63M -5.02B | EV / Sales 2024 * | - |
Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 510 x |
P/E ratio 2024 * |
-2.57
x | P/E ratio 2025 * |
-2.37
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.99% |
Latest transcript on Edge Therapeutics Inc
Managers | Title | Age | Since |
---|---|---|---|
Frank Bedu-Addo
FOU | Founder | 59 | 14/03/19 |
Director of Finance/CFO | 55 | 12-03 | |
David Schaaf
CTO | Chief Tech/Sci/R&D Officer | - | 31/08/22 |
Members of the board | Title | Age | Since |
---|---|---|---|
Stephen Glover
CHM | Chairman | 60 | 01/04/19 |
Otis Brawley
BRD | Director/Board Member | 64 | 02/11/20 |
Richard Sykes
BRD | Director/Board Member | 79 | 28/02/19 |
1st Jan change | Capi. | |
---|---|---|
+8.96% | 105B | |
-1.43% | 104B | |
+4.40% | 22.94B | |
-12.15% | 22.34B | |
-4.36% | 19.25B | |
-39.98% | 17.08B | |
-10.04% | 16.96B | |
+38.61% | 12.63B | |
+313.59% | 8.49B |